GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
GSK PHARMA Mar-19 |
ADCOCK INGRAM Jun-14 |
GSK PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 3,595 | 354 | - | |
Low | Rs | 1,253 | 255 | - | |
Sales per share (Unadj.) | Rs | 184.7 | 105.2 | - | |
Earnings per share (Unadj.) | Rs | 26.3 | -26.5 | - | |
Cash flow per share (Unadj.) | Rs | 29.2 | -22.0 | - | |
Dividends per share (Unadj.) | Rs | 20.00 | 0 | - | |
Dividend yield (eoy) | % | 0.8 | 0 | - | |
Book value per share (Unadj.) | Rs | 126.3 | 82.6 | - | |
Shares outstanding (eoy) | m | 169.40 | 168.78 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 13.1 | 2.9 | 453.7% | |
Avg P/E ratio | x | 92.2 | -11.5 | -802.9% | |
P/CF ratio (eoy) | x | 83.1 | -13.9 | -599.9% | |
Price / Book Value ratio | x | 19.2 | 3.7 | 520.6% | |
Dividend payout | % | 76.1 | 0 | - | |
Avg Mkt Cap | Rs m | 410,626 | 51,396 | 799.0% | |
No. of employees | `000 | 5.0 | 4.3 | 115.5% | |
Total wages/salary | Rs m | 5,372 | 3,226 | 166.5% | |
Avg. sales/employee | Rs Th | 6,306.7 | 4,137.7 | 152.4% | |
Avg. wages/employee | Rs Th | 1,083.1 | 751.4 | 144.1% | |
Avg. net profit/employee | Rs Th | 898.0 | -1,042.6 | -86.1% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 31,281 | 17,763 | 176.1% | |
Other income | Rs m | 1,023 | 124 | 822.5% | |
Total revenues | Rs m | 32,304 | 17,888 | 180.6% | |
Gross profit | Rs m | 6,009 | -3,078 | -195.2% | |
Depreciation | Rs m | 486 | 767 | 63.4% | |
Interest | Rs m | 6 | 481 | 1.2% | |
Profit before tax | Rs m | 6,540 | -4,202 | -155.7% | |
Minority Interest | Rs m | 0 | -12 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 287 | 0 | - | |
Tax | Rs m | 2,373 | 263 | 903.8% | |
Profit after tax | Rs m | 4,454 | -4,476 | -99.5% | |
Gross profit margin | % | 19.2 | -17.3 | -110.8% | |
Effective tax rate | % | 36.3 | -6.2 | -580.7% | |
Net profit margin | % | 14.2 | -25.2 | -56.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 20,061 | 13,010 | 154.2% | |
Current liabilities | Rs m | 14,543 | 7,320 | 198.7% | |
Net working cap to sales | % | 17.6 | 32.0 | 55.1% | |
Current ratio | x | 1.4 | 1.8 | 77.6% | |
Inventory Days | Days | 57 | 111 | 51.2% | |
Debtors Days | Days | 14 | 124 | 11.3% | |
Net fixed assets | Rs m | 14,343 | 7,584 | 189.1% | |
Share capital | Rs m | 1,694 | 82 | 2,054.0% | |
Net worth | Rs m | 21,398 | 13,942 | 153.5% | |
Long term debt | Rs m | 2 | 4,900 | 0.0% | |
Total assets | Rs m | 39,113 | 26,338 | 148.5% | |
Interest coverage | x | 1,091.0 | -7.7 | -14,109.7% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.8 | 0.7 | 118.6% | |
Return on assets | % | 11.4 | -15.2 | -75.2% | |
Return on equity | % | 20.8 | -32.1 | -64.8% | |
Return on capital | % | 31.9 | -19.8 | -161.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,994 | 1,516 | 263.4% | |
From Investments | Rs m | -1,433 | -466 | 307.9% | |
From Financial Activity | Rs m | -3,584 | 4,447 | -80.6% | |
Net Cashflow | Rs m | -1,023 | 5,497 | -18.6% |
Compare GSK PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare GSK PHARMA With: VENUS REMEDIES STRIDES PHARMA SCIENCE LUPIN SUN PHARMA DR. DATSONS LABS
Indian share markets witnessed positive trading activity throughout the day today and ended on a strong note.
For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
In this video, I'll show you how to get started on the path to daily trading profits.
More